INPACT · Innovative peptides against cancer and pathogenic bacteria, with advances in science, biopharmaceutical drug development, product market targeting, training , and communication.
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2015-02-01 → 2019-01-31
- EU contribution
- €850,500
- Participants
- 10
- Scheme
- MSCA-RISE
Lines connect the coordinator with its partners.
Results in brief
Innovative peptides against cancer and pathogenic bacteria, with advances in science, biopharmaceutical drug development, product market targeting, training , and communication.
INPACT has a collaborative academic and industrial R&D team that combines specific technologies and expertise in peptide science, proprietary technologies on antibody and protein engineering, and experience in development of antimicrobial and anticancer drugs. Together this team has the ability to produce novel drugs with higher selectivity, lower likelihood to develop resistance, and with improved delivery, when compared to current drugs in the market. The INPACT team includes of five academic partners (from Portugal, Spain, Australia, Brazil, and USA) and three biotech SMEs committed to R&D (from Portugal and Spain), all strongly engaged in INPACT. In addition to the academic and industry partners, INPACT also involves a world leader European business school (IESE, Barcelona, Spain) and an established media partner specialised in science communication (Ciência Hoje, Rio de Janeiro, Brazil). This team has been working at the interface of basic and pre-clinical research to translate the outcomes into technologies of industrial value. Overall, INPACT will contribute to the progress of Europe by using research and education for societal development and economic growth. The major outcome intended for the project is to develop new drug leads to target both infectious diseases and cancers. Specifically, the new drugs will combine the ability to kill bacteria and tumour cells with capability to translocate the blood-brain barrier; therefore, these innovative drugs will be capable of targeting brain tumors and brain-hidden pathogens.
Data: CORDIS, © European Union
Project objective
INPACT aims at the pre-clinical development of innovative drugs and drug formulations against selected cancers (eg prostate cancer) and pathogenic bacteria (eg S. aureus). The INPACT consortium allies the expertise of both academic and industrial R&D partners that contribute with their own unique technologies to achieve new drugs that are only possible to develop in an integrative effort. Academic partners have unique knowledge and technologies on supercharged viral proteins-derived cell-penetrating peptides (eg from Dengue virus) and ultra-resistant cyclic peptides that may be transferred to the industrial partners, which in turn have specialized proprietary technologies on anticancer and/or peptide drugs’ technologies. The judicious exchange of knowledge among partners will lead to new resistant peptides for trans-barrier delivery of drugs (eg cyclic peptide-drug chimeras) and bacterial killing (both planktonic and biofilms). INPACT includes four leading academic partners (from Portugal, Spain, Australia, and Brazil) and three consolidated biotech SMEs (one from Portugal and two Spain).In addition to the R&D project itself, INPACT involves at the highest possible level a top business school in Europe (IESE, Barcelona, Spain), a consolidated media partner specialised in science communication (Ciencia Hoje, Rio de Janeiro, Brazil) and experts in international science funding from one of the top US universities (University of Stanford). The consortium will be the perfect environment for young researchers to acquire knowledge and skills in science, technology, entrepreneurship, business, and communication so they can pro-actively tailor their career path in a life-long learning perspective. This is a contribution towards the advancement of Europe through the use of research and education for societal development and economic growth.
Original text from CORDIS.
Participants
- INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES · LisboaCoordinatorPortugal
- BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY · STANFORDUnited States
- CENTRO ATLANTICO DEL MEDICAMENTO, SA · SAN CRISTOBAL DE LA LAGUNA TENERIFESpain
- INSTITUTO CIENCIA HOJE-ICH · RIO DE JANEIROBrazil
- PROTEODESIGN SL · BarcelonaSpain
- TECHNOPHAGE INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA SA · LISBOAPortugal
- THE UNIVERSITY OF QUEENSLAND · BrisbaneAustralia
- UNIVERSIDAD DE NAVARRA · PamplonaSpain
- UNIVERSIDAD POMPEU FABRA · BarcelonaSpain
- UNIVERSIDADE FEDERAL DO RIO DE JANEIRO · RIO DE JANEIROBrazil
Links
- View on CORDIS
- DOI: 10.3030/644167
- http://web.archive.org/web/20180807163414/https://rise-inpact.com/
- https://ec.europa.eu/research-and-innovation/en/projects/success-stories/all/breaking-down-barriers-develop-new-anticancer-drugs
- https://www.ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c2a3d771&appId=PPGMS
- https://www.ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c2a3e587&appId=PPGMS
- https://www.ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c2a50065&appId=PPGMS
- https://www.ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c2a50068&appId=PPGMS
Data: CORDIS, © European Union